Characterization of a universal screening approach for congenital CMV infection based on a highly-sensitive, quantitative, multiplex real-time PCR assay.
Cytomegalovirus
/ genetics
Cytomegalovirus Infections
/ diagnosis
DNA, Viral
/ genetics
Female
Humans
Infant, Newborn
Infant, Newborn, Diseases
/ blood
Male
Multiplex Polymerase Chain Reaction
/ methods
Neonatal Screening
/ methods
Real-Time Polymerase Chain Reaction
/ methods
Saliva
/ virology
Urine
/ virology
Viral Load
Viremia
/ diagnosis
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
07
2019
accepted:
12
12
2019
entrez:
10
1
2020
pubmed:
10
1
2020
medline:
6
5
2020
Statut:
epublish
Résumé
The majority of congenital cytomegalovirus (cCMV) infections are asymptomatic at birth and therefore not diagnosed. Approximately 10-15% of these infants develop late-onset hearing loss and other developmental disorders. Implementation of a universal screening approach at birth may allow early initiation of symptomatic interventions due to a closer follow-up of infants at risk and offers the opportunity to consider treatment of late-onset disease. Real-time PCR assays for the detection of CMV DNA in buccal swab samples demonstrated feasibility and good clinical sensitivity in comparison to a rapid culture screening assay. Because most cCMV infections remain asymptomatic, a universal screening assay that stratifies CMV infected infants according to low and high risk of late-onset cCMV disease could limit the parental anxiety and reduce follow-up costs. We therefore developed and characterized a screening algorithm based on a highly-sensitive quantitative real-time PCR assay that is compatible with centralized testing of samples from universal screening and allows to determine CMV DNA load of saliva samples either as International Units (IU)/ml saliva or IU/105 cell equivalents. 18 of 34 saliva samples of newborns that tested positively by the screening algorithm were confirmed by detection of CMV DNA in blood and/or urine samples obtained during the first weeks of life. All screening samples that could not be confirmed had viral loads of <2.3x105 IU/ml saliva (median: 6.8x103) or 1.3x105 IU/105 cell equivalents (median: 4.0x102). The viral load of screening samples with confirmed cCMV infection ranged from 7.5x102 to 8.2x109 IU/ml saliva (median: 9.3x107) or 1.5x102 to 5.6x1010 IU/105 cell equivalents (median: 3.5x106). Clinical follow-up of these newborns with confirmed cCMV infection should reveal whether the risk of late-onset cCMV disease correlates with CMV DNA load in early life saliva samples and whether a cut-off can be defined identifying cCMV infected infants with or without risk for late-onset cCMV disease.
Identifiants
pubmed: 31917817
doi: 10.1371/journal.pone.0227143
pii: PONE-D-19-21434
pmc: PMC6952102
doi:
Substances chimiques
DNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0227143Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Eur J Pediatr. 2015 Aug;174(8):1117-21
pubmed: 25743117
Rev Med Virol. 2007 Sep-Oct;17(5):355-63
pubmed: 17542052
Rev Soc Bras Med Trop. 2015 Mar-Apr;48(2):206-7
pubmed: 25992937
Pediatr Infect Dis J. 2019 May;38(5):520-524
pubmed: 30199483
J Infect Dis. 2018 Apr 23;217(10):1612-1615
pubmed: 29401303
Pediatr Infect Dis J. 2015 May;34(5):536-7
pubmed: 25876092
Rev Med Virol. 2014 Sep;24(5):291-307
pubmed: 24760655
Front Pediatr. 2016 Aug 31;4:93
pubmed: 27630978
Pediatrics. 2017 Feb;139(2):
pubmed: 28049114
J Infect Dis. 2019 Oct 22;220(11):1790-1796
pubmed: 31310307
Open Forum Infect Dis. 2015 Dec 09;3(1):ofv193
pubmed: 26817022
J Clin Virol. 2006 Jul;36(3):228-30
pubmed: 16750653
J Clin Virol. 2019 Jun;115:32-36
pubmed: 30959324
BMC Infect Dis. 2014 Nov 13;14:569
pubmed: 25391640
Infection. 2012 Apr;40(2):181-4
pubmed: 22350961
JAMA Pediatr. 2016 Dec 1;170(12):1173-1180
pubmed: 27723885
JAMA. 2010 Apr 14;303(14):1375-82
pubmed: 20388893
J Clin Virol. 2019 Aug;117:33-36
pubmed: 31176209
Arch Dis Child. 2019 Jun;104(6):559-563
pubmed: 30472664
J Virol. 2017 May 26;91(12):
pubmed: 28381570
PLoS One. 2013 Apr 16;8(4):e61703
pubmed: 23613907
Clin Infect Dis. 2017 Aug 1;65(3):398-404
pubmed: 28419213
Lancet Infect Dis. 2017 Jun;17(6):e177-e188
pubmed: 28291720
J Infect Dis. 2019 Apr 16;219(9):1398-1406
pubmed: 30535363
Expert Rev Anti Infect Ther. 2017 May;15(5):417-419
pubmed: 28277819
Arch Dis Child Fetal Neonatal Ed. 2013 Mar;98(2):F182
pubmed: 22874907
J Infect Dis. 1993 Jun;167(6):1433-6
pubmed: 8388905
J Clin Virol. 2014 Aug;60(4):361-6
pubmed: 24881490
Rev Med Virol. 2011 Jul;21(4):240-55
pubmed: 21674676
J Pediatric Infect Dis Soc. 2018 Aug 17;7(3):e160-e162
pubmed: 29860410
PLoS One. 2009 Sep 10;4(9):e6985
pubmed: 19746164
Ital J Pediatr. 2017 Apr 17;43(1):38
pubmed: 28416012
J Pediatr. 2017 May;184:57-61.e1
pubmed: 28237380
N Engl J Med. 2011 Jun 2;364(22):2111-8
pubmed: 21631323